文献速递中医内科中药与中成药合理使用

中药联合奥沙利铂化疗治疗晚期胃癌的系统评价与meta分析

Chinese herbal medicine combined with oxaliplatin-based chemotherapy for advanced gastric cancer: A systematic review and meta-analysis of contributions of specific medicinal materials to tumor response.
PubMed 文献 · Front Pharmacol · 2022-08-25

Meta分析显示联合治疗提高客观缓解率35%和疾病控制率12%,敏感性分析识别出7种可能改善肿瘤反应的药材。证据质量为中等确定性。

要点

  • 中药联合奥沙利铂化疗可提高晚期胃癌客观缓解率和疾病控制率。
  • 黄芪、甘草、茯苓、白术、当归、党参、陈皮可能改善肿瘤反应。
  • 联合治疗安全性较好,但纳入研究质量偏低、样本量小。

核心结论

  • 中药联合奥沙利铂化疗可能改善晚期胃癌肿瘤反应,证据质量为中等确定性。
  • 中药治疗对晚期胃癌是安全的。
  • 特定药材组合对客观缓解率的贡献可能高于单味药材。

研究设计与样本

  • 系统评价与meta分析,检索PubMed、EMBASE、CENTRAL、Web of Science及4个中文数据库至2022年4月。
  • 使用Stata 16进行数据合成,RoB 2评估偏倚风险,GRADE评估证据质量。

主要发现

  • 与单纯奥沙利铂化疗相比,中药联合治疗提高客观缓解率35%[RR=1.35,95%CI(1.25,1.45)]。
  • 中药联合治疗提高疾病控制率12%[RR=1.12,95%CI(1.08,1.16)]。
  • 亚组分析显示中药联合SOX、FOLFOX、XELOX方案均可显著提高客观缓解率和疾病控制率。
  • 敏感性分析识别出黄芪、甘草、茯苓、白术、当归、党参、陈皮7种药材可能改善肿瘤反应。

关键数值与推荐

  • 客观缓解率RR=1.35,95%CI(1.25,1.45)。
  • 疾病控制率RR=1.12,95%CI(1.08,1.16)。
  • 多数纳入RCT偏倚风险评为「有些担忧」。

临床怎么用

  • 在奥沙利铂化疗基础上可考虑联合中药以改善肿瘤反应。
  • 组方时可优先考虑黄芪、甘草、茯苓、白术、当归、党参、陈皮等药材。
  • 需结合患者具体情况辨证使用,并关注化疗毒性反应。

局限性

  • 纳入RCT质量较差,多数存在偏倚风险「有些担忧」。
  • 样本量小,合成证据质量不高。
  • 需要进一步开展高质量临床研究验证7种药材的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Introduction: The incidence and mortality of gastric cancer ranks among the highest, and the 5-year survival rate of advanced gastric cancer (AGC) is less than 10%. Currently, chemotherapy is the main treatment for AGC, and oxaliplatin is an important part of the commonly used chemotherapy regimen for AGC. A large number of RCTs have shown that Chinese herbal medicine (CHM) combined with oxaliplatin-based chemotherapy can improve objective response rate (ORR) and disease control rate (DCR), reduce the toxic and side effects of chemotherapy. There is currently a lack of systematic evaluation of the evidence to account for the efficacy and safety of CHM combined with oxaliplatin-based chemotherapy in AGC. Therefore, we carried out this study and conducted the sensitivity analysis on the herbal composition to explore the potential anti-tumor efficacy. Methods: Databases of PubMed, EMBASE, CENTRAL, Web of Science, the Chinese Biomedical Literature Database, the China National Knowledge Infrastructure, the Wanfang database, and the Chinese Scientific Journals Database were searched from their inception to April 2022. RCTs evaluating the efficacy of CHM combined with oxaliplatin-based chemotherapy on AGC were included. Stata 16 was used for data synthesis, RoB 2 for quality evaluation of included RCTs, and GRADE for quality of synthesized evidence. Additional sensitivity analysis was performed to explore the potential anti-tumor effects of single herbs and combination of herbs. Results: Forty trials involving 3,029 participants were included. Most included RCTs were assessed as "Some concerns" of risk of bias. Meta-analyses showed that compare to oxaliplatin-based chemotherapy alone, that CHM combined with oxaliplatin-based chemotherapy could increase the objective response rate (ORR) by 35% [risk ratio (RR) = 1.35, 95% confidence intervals (CI) (1.25, 1.45)], and disease control rate (DCR) by 12% [RR = 1.12, 95% CI (1.08, 1.16)]. Subgroup analysis showed that compare to SOX, FOLFOX, and XELOX regimens alone, CHM plus SOX, CHM plus FOLFOX, and CHM plus XELOX could significantly increase the ORR and DCR. Sensitivity analysis identified seven herbs of Astragalus, Liquorice, Poria, Largehead Atractylodes, Chinese Angelica, Codonopsis, and Tangerine Peel with potentials to improve tumor response of oxaliplatin-based chemotherapy in AGC. Conclusion: Synthesized evidence showed moderate certainty that CHM plus oxaliplatin-based chemotherapy may promote improvement in tumor response in AGC. CHM treatment is safe for AGC. Due to the poor quality of included RCTs and small samplesizes, the quality of synthesized evidence was not high. Specific combinations of herbs appeared to produce higher contributions to ORR than the herb individually. Each of this seven above mentioned herbs has been shown in experimental studies to potentially contribute to the improvement of tumor response. To support this conclusion, these seven herbs are worthy of further clinical research. Systematic Review Registration: [http://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=262595], identifier [CRD42022262595].

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Tan Y, Wang H, Xu B, et al. Chinese herbal medicine combined with oxaliplatin-based chemotherapy for advanced gastric cancer: A systematic review and meta-analysis of contributions of specific medicinal materials to tumor response. Front Pharmacol. 2022. PMID: 36091754. doi:10.3389/fphar.2022.977708

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。